Deciphex is at the forefront of revolutionizing pathology through the integration of artificial intelligence (AI) and digital workflows. Their innovative approach aims to democratize access to high-quality pathology services by creating a global network of AI-empowered pathologists. This network addresses the increasing demand for diagnostic services, particularly in underserved areas, by providing rapid and accurate diagnostics remotely. Their platform, Diagnexia, has significantly reduced wait times for pathology results in the NHS from two months to just two days, thereby enhancing healthcare efficiency and improving patient outcomes.

In the pharmaceutical sector, Deciphex's Patholytix platform is transforming drug development processes for leading companies by enabling faster and more thorough testing of drug candidates. The platform adheres to Good Laboratory Practice (GLP) standards, ensuring compliance and accuracy in safety assessments. By automating study management and integrating AI-driven decision support, Patholytix streamlines workflows, reduces the reliance on animal testing, and accelerates the identification of promising drug candidates. This comprehensive approach not only enhances the reliability of preclinical research but also facilitates quicker market access for innovative therapies, ultimately contributing to safer patient outcomes.

Ireland

Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes.

The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload.

We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.

Various

DCU Alpha Building, Innovation Campus, 11 Old Finglas Rd, Glasnevin, Co. Dublin, D11 KXN4, Ireland

Deciphex

Company Details